Thymosin Alpha-1

An immune-modulating peptide approved as a drug in multiple countries for immune support.

Tα1Ta1Zadaxin

Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland. It is one of the few peptides that has been approved as a pharmaceutical drug (Zadaxin) in multiple countries for immune modulation. It enhances the immune system by stimulating T-cell maturation, dendritic cell function, and antibody responses. It has been used clinically for hepatitis B/C, immune deficiencies, and as an adjunct in cancer immunotherapy.

Key Benefits

Immune Enhancement

Stimulates maturation of T-cells, enhances dendritic cell function, and improves overall adaptive immune response.

Viral Defense

Clinically used for hepatitis B and C treatment. Research shows improved viral clearance and enhanced antiviral immunity.

Cancer Immunotherapy Adjunct

Used alongside chemotherapy and immunotherapy to improve immune function and reduce treatment-related immunosuppression.

Vaccine Enhancement

Acts as an immune adjuvant, improving antibody response to vaccines, particularly in immunocompromised individuals.

Anti-Inflammatory Balance

Modulates the immune response toward balanced activity — enhancing weak immune function while reducing excessive inflammation.

Infection Recovery

Supports recovery from chronic infections and has been studied in sepsis, CMV, and opportunistic infections.

Research Dosing Information

Common Dose

1.6 mg per injection

Route

Subcutaneous injection

Frequency

2-3 times per week

Cycle Length

4-26 weeks depending on condition

Approved as Zadaxin in over 35 countries (not FDA-approved in the US). The 1.6 mg dose is the standard pharmaceutical dose used in clinical trials. Typically well-tolerated with minimal side effects.

Research Summary

Thymosin Alpha-1 has one of the strongest clinical research profiles of any peptide. Over 4,400 patients have been treated in clinical trials. It is approved in 35+ countries for hepatitis B treatment and immune enhancement. Research demonstrates improved T-cell function, enhanced dendritic cell maturation, and better vaccine response. Notable studies include its use in hepatitis B/C (improved viral clearance), melanoma (adjunct immunotherapy), and sepsis (reduced mortality in critically ill patients).

Safety Considerations

Approved pharmaceutical in 35+ countries with established safety profile.
Not FDA-approved in the United States.
Most common side effect is mild injection site discomfort.
No significant drug interactions reported in clinical trials.
Considered one of the safest peptides due to extensive clinical use.
Avoid in organ transplant recipients (may reduce immunosuppression).

Frequently Asked Questions

Is Thymosin Alpha-1 FDA-approved?

Not in the United States. However, it is approved as Zadaxin in over 35 countries including parts of Asia, Europe, and South America for hepatitis B treatment and immune modulation.

Can Thymosin Alpha-1 help with autoimmune conditions?

Research suggests it can modulate — not just boost — immunity. It may help rebalance immune responses. However, use in autoimmune conditions should be carefully supervised by a physician.

How is Thymosin Alpha-1 different from Thymosin Beta-4?

They are entirely different peptides with different functions. Alpha-1 is primarily an immune modulator (T-cell activation), while Beta-4 (TB-500) is focused on tissue repair and wound healing.